Tuberculosis treatment outcomes among disadvantaged patients in India

por Jackson, C., Stagg, H. R., Doshi, A., Pan, D., Sinha, A., Batra, R., Batra, S., Abubakar, I., Lipman, M.
Publicado 2017

What are the most efficacious treatment regimens for isoniazid-resistant tuberculosis? A systematic review and network meta-analysis

por Stagg, H R, Harris, R J, Hatherell, H-A, Obach, D, Zhao, H, Tsuchiya, N, Kranzer, K, Nikolayevskyy, V, Kim, J, Lipman, M C, Abubakar, I
Publicado 2016

An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot stu...

por Surey, J., Stagg, H. R., Yates, T. A., Lipman, M., White, P. J., Charlett, A., Muñoz, L., Gosce, L., Rangaka, M. X., Francis, M., Hack, V., Kunst, H., Abubakar, I.
Publicado 2021

Informing the public health response to COVID-19: a systematic review of risk factors for disease, severity, and mortality

por Flook, M., Jackson, C., Vasileiou, E., Simpson, C. R., Muckian, M. D., Agrawal, U., McCowan, C., Jia, Y., Murray, J. L. K., Ritchie, L. D., Robertson, C., Stock, S. J., Wang, X., Woolhouse, M. E. J., Sheikh, A., Stagg, H. R.
Publicado 2021

First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland

por Simpson, C. R., Shi, T., Vasileiou, E., Katikireddi, S. V., Kerr, S., Moore, E., McCowan, C., Agrawal, U., Shah, S. A., Ritchie, L. D., Murray, J., Pan, J., Bradley, D. T., Stock, S. J., Wood, R., Chuter, A., Beggs, J., Stagg, H. R., Joy, M., Tsang, R. S. M., de Lusignan, S., Hobbs, R., Lyons, R. A., Torabi, F., Bedston, S., O’Leary, M., Akbari, A., McMenamin, J., Robertson, C., Sheikh, A.
Publicado 2021